Drug Profile
Valemetostat - Daiichi Sankyo
Alternative Names: DS-3201; DS-3201b; EZHARMIA; Valemetostat tosilate; valemetostat tosylateLatest Information Update: 25 Apr 2024
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Inc
- Developer CALYM Carnot Institute; Daiichi Sankyo Inc; Lymphoma Academic Research Organisation; Lymphoma Study Association; University of Texas M. D. Anderson Cancer Center
- Class Amides; Amines; Antineoplastics; Benzodioxoles; Chlorinated hydrocarbons; Cyclohexanes; Pyridones; Small molecules
- Mechanism of Action Enhancer of zeste homolog 1 protein inhibitors; Enhancer of zeste homolog 2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Adult T-cell leukaemia-lymphoma
- Phase II B-cell lymphoma; Peripheral T-cell lymphoma
- Phase I/II Small cell lung cancer
- Phase I Adenocarcinoma; Non-small cell lung cancer
- No development reported Acute myeloid leukaemia; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer; Renal cell carcinoma; Urogenital cancer
Most Recent Events
- 16 Feb 2024 Phase-I clinical trials in Adenocarcinoma (Combination therapy, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater, Late-stage disease) in USA (PO) (NCT06244485)
- 16 Feb 2024 Phase-I clinical trials in Non-small cell lung cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT06244485)
- 06 Feb 2024 Daiichi Sankyo Company plans a phase I trial for Solid tumors (Late-stage-diseases, Metastatic-diseases, Combination therapy) (NCT06244485, DS3201-324)